26S proteasome — Drug Target

All drugs that target 26S proteasome — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Proteasome inhibitor · Proteasome inhibitor combined with chemotherapy

Marketed (1)

• Bortezomib (B) · National Cancer Institute (NCI) · Proteasome inhibitor · Oncology
  Bortezomib inhibits the 26S proteasome, preventing the degradation of proteins that regulate cell cycle and apoptosis, leading to cancer cell death.

Phase 3 pipeline (2)

• CDD Plus Bortezomib · Beijing Chao Yang Hospital · Proteasome inhibitor combined with chemotherapy · Oncology
  CDD Plus Bortezomib combines a chemotherapy regimen (CDD) with bortezomib, a proteasome inhibitor that blocks protein degradation to trigger cancer cell death.
• VELCADE Administered by intravenous infusion · Millennium Pharmaceuticals, Inc. · Proteasome inhibitor · Oncology
  VELCADE (bortezomib) is a proteasome inhibitor that blocks the degradation of proteins, causing cancer cells to accumulate toxic protein levels and undergo apoptosis.

Phase 2 pipeline (1)

• Bortezomib, Dexamethasone, Rituximab · European Myeloma Network B.V. · Proteasome inhibitor · Oncology
  Bortezomib inhibits the 26S proteasome, disrupting protein degradation and inducing apoptosis in cancer cells.